Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 300.
ZANTAC 150 vs ZANTAC 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits basal and stimulated gastric acid secretion by blocking H2 receptors on parietal cells in the stomach.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
150 mg orally twice daily or 300 mg orally once daily at bedtime.
300 mg orally once daily at bedtime or 150 mg orally twice daily.
None Documented
None Documented
2.5 hours (range 1.5-3.5 h); prolonged in renal impairment (creatinine clearance <50 mL/min: 4-8 h).
Approximately 2.5–3 hours in patients with normal renal function; prolonged in renal impairment (creatinine clearance <30 mL/min: up to 6–12 hours).
Renal (70% unchanged via tubular secretion), biliary (30% as metabolites and unchanged drug).
Renal (approximately 30% unchanged active drug via tubular secretion and glomerular filtration); hepatic metabolism to N-oxide, S-oxide, and desmethyl metabolites (about 70% of dose); fecal excretion (minor, <5%).
Category C
Category C
H2 Antagonist
H2 Antagonist